Literature DB >> 15095031

Dopamine D3 receptor ligands modulate the acquisition of morphine-conditioned place preference.

Henriette Francès1, Maria Smirnova, Ludovic Leriche, Pierre Sokoloff.   

Abstract

RATIONALE: The dopamine D3 receptor has been shown to mediate conditioned effects of psychostimulants such as cocaine. The present work was aimed at determining whether drugs acting at D3 receptors alter acquisition of conditioned effects of opiates.
METHODS: We have used the conditioned place preference (CPP) in mice, which permits the measurement of approach behaviour to environmental stimuli previously paired with drug effects. To assess the interaction of morphine and D3 receptor ligands during acquisition of CPP, we have used a particular procedure, in which the animals were given the choice between compartments associated with either morphine alone or the combination of morphine with the tested agent.
RESULTS: D3 receptor agonists (7-OH-DPAT, quinelorane, BP 897) did not induce, alone, a significant CPP but, all of them, at the doses tested, and notably BP 897, a highly selective partial agonist, significantly enhanced acquisition of morphine-induced CPP when administered together with morphine at each conditioning session. PNU-99194A, a D3 receptor-preferring antagonist, induced a CPP itself at the dose of 10 mg/kg but not at 5 or 15 mg/kg and impaired significantly at 10 and 15 mg/kg the morphine-induced CPP. In contrast, BP 897 did not alter morphine-induced analgesia, an unconditioned effect of this drug.
CONCLUSIONS: These results suggest the stimulation of D3 receptors has no rewarding effect per se, but may synergize upon opiate-induced dopamine release with stimulation of other dopamine receptor subtypes to enhance approach behaviour to morphine-associated environment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15095031     DOI: 10.1007/s00213-004-1807-9

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  57 in total

1.  Selective D3 receptor agonist effects of (+)-PD 128907 on dialysate dopamine at low doses.

Authors:  A Zapata; J M Witkin; T S Shippenberg
Journal:  Neuropharmacology       Date:  2001-09       Impact factor: 5.250

2.  The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and D-amphetamine and is not self-administered.

Authors:  P M Beardsley; P Sokoloff; R L Balster; J C Schwartz
Journal:  Behav Pharmacol       Date:  2001-02       Impact factor: 2.293

3.  Role of dopamine D3 receptors in thermoregulation: a reappraisal.

Authors:  S Perachon; C Betancur; C Pilon; W Rostène; J C Schwartz; P Sokoloff
Journal:  Neuroreport       Date:  2000-01-17       Impact factor: 1.837

4.  Dopamine D3 receptors expressed by all mesencephalic dopamine neurons.

Authors:  J Diaz; C Pilon; B Le Foll; C Gros; A Triller; J C Schwartz; P Sokoloff
Journal:  J Neurosci       Date:  2000-12-01       Impact factor: 6.167

5.  Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.

Authors:  C Reavill; S G Taylor; M D Wood; T Ashmeade; N E Austin; K Y Avenell; I Boyfield; C L Branch; J Cilia; M C Coldwell; M S Hadley; A J Hunter; P Jeffrey; F Jewitt; C N Johnson; D N Jones; A D Medhurst; D N Middlemiss; D J Nash; G J Riley; C Routledge; G Stemp; K M Thewlis; B Trail; A K Vong; J J Hagan
Journal:  J Pharmacol Exp Ther       Date:  2000-09       Impact factor: 4.030

6.  Effects on locomotor activity after local application of D3 preferring compounds in discrete areas of the rat brain.

Authors:  T Kling-Petersen; E Ljung; K Svensson
Journal:  J Neural Transm Gen Sect       Date:  1995

7.  The dopamine receptor agonist 7-OH-DPAT modulates the acquisition and expression of morphine-induced place preference.

Authors:  F Rodríguez De Fonseca; P Rubio; J L Martín-Calderón; S B Caine; G F Koob; M Navarro
Journal:  Eur J Pharmacol       Date:  1995-02-14       Impact factor: 4.432

8.  Examination of the neurochemical substrates mediating the motivational effects of opioids: role of the mesolimbic dopamine system and D-1 vs. D-2 dopamine receptors.

Authors:  T S Shippenberg; R Bals-Kubik; A Herz
Journal:  J Pharmacol Exp Ther       Date:  1993-04       Impact factor: 4.030

9.  Autoradiographic evidence for the occlusion of rat brain dopamine D3 receptors in vivo.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; J E Leysen
Journal:  Eur J Pharmacol       Date:  1992-08-06       Impact factor: 4.432

10.  Attenuation of cue-controlled cocaine-seeking by a selective D3 dopamine receptor antagonist SB-277011-A.

Authors:  Patricia Di Ciano; Rachel J Underwood; Jim J Hagan; Barry J Everitt
Journal:  Neuropsychopharmacology       Date:  2002-06-18       Impact factor: 7.853

View more
  6 in total

Review 1.  Neuronal circuitry underlying the impact of D3 receptor ligands in drug addiction.

Authors:  Bernard Le Foll; Patricia Di Ciano
Journal:  Eur Neuropsychopharmacol       Date:  2014-09-16       Impact factor: 4.600

2.  TREK1 channel activation as a new analgesic strategy devoid of opioid adverse effects.

Authors:  Jérôme Busserolles; Ismail Ben Soussia; Laetitia Pouchol; Nicolas Marie; Mathieu Meleine; Maïly Devilliers; Céline Judon; Julien Schopp; Loïc Clémenceau; Laura Poupon; Eric Chapuy; Serge Richard; Florence Noble; Florian Lesage; Sylvie Ducki; Alain Eschalier; Stéphane Lolignier
Journal:  Br J Pharmacol       Date:  2020-09-21       Impact factor: 8.739

3.  The novel dopamine D3 receptor antagonists/partial agonists CAB2-015 and BAK4-54 inhibit oxycodone-taking and oxycodone-seeking behavior in rats.

Authors:  Zhi-Bing You; Jun-Tao Gao; Guo-Hua Bi; Yi He; Comfort Boateng; Jianjing Cao; Eliot L Gardner; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2017-09-06       Impact factor: 5.250

4.  Maternal deprivation and handling modify the effect of the dopamine D3 receptor agonist, BP 897 on morphine-conditioned place preference in rats.

Authors:  Vincent Vazquez; Stéphanie Weiss; Bruno Giros; Marie-Pascale Martres; Valérie Daugé
Journal:  Psychopharmacology (Berl)       Date:  2007-05-10       Impact factor: 4.415

5.  (±)VK4-40, a novel dopamine D3 receptor partial agonist, attenuates cocaine reward and relapse in rodents.

Authors:  Chloe J Jordan; Yi He; Guo-Hua Bi; Zhi-Bing You; Jianjing Cao; Zheng-Xiong Xi; Amy Hauck Newman
Journal:  Br J Pharmacol       Date:  2020-09-17       Impact factor: 9.473

Review 6.  Dopamine D3 receptor-based medication development for the treatment of opioid use disorder: Rationale, progress, and challenges.

Authors:  Ewa Galaj; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neurosci Biobehav Rev       Date:  2020-05-03       Impact factor: 8.989

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.